Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 6
Submit an article Journal homepage
373
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Venetoclax and azacitidine (VenAZA) combination therapy in young unfit patients with AML: a perspective from a developing country

Jayastu SenapatiDepartment of Haematology, All India Institute of Medical Sciences, New Delhi, IndiaORCID Iconhttps://orcid.org/0000-0002-6831-2567
ORCID Icon,
Rishi DhawanDepartment of Haematology, All India Institute of Medical Sciences, New Delhi, India
,
Mukul AggarwalDepartment of Haematology, All India Institute of Medical Sciences, New Delhi, India
,
Pradeep KumarDepartment of Haematology, All India Institute of Medical Sciences, New Delhi, India
,
Ganesh Kumar VishwanathanDepartment of Haematology, All India Institute of Medical Sciences, New Delhi, India
,
Jasmita DassDepartment of Haematology, All India Institute of Medical Sciences, New Delhi, India
,
Seema TyagiDepartment of Haematology, All India Institute of Medical Sciences, New Delhi, India
,
Manoranjan MahapatraDepartment of Haematology, All India Institute of Medical Sciences, New Delhi, India
&
Tulika SethDepartment of Haematology, All India Institute of Medical Sciences, New Delhi, IndiaCorrespondence[email protected]
 show all
Pages 1514-1517 | Received 13 Oct 2020, Accepted 12 Dec 2020, Published online: 15 Jan 2021

References

  • Major CK, Kantarjian H, Sasaki K, et al. Survivorship in AML – a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma. 2020;61(13):1–8.
  • Lachowiez C, DiNardo CD, Konopleva M. Venetoclax in acute myeloid leukemia – current and future directions. Leuk Lymphoma. 2020;61(6):1313–1322.
  • DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
  • Philip C, George B, Ganapule A, et al. Acute myeloid leukaemia: challenges and real world data from India. Br J Haematol. 2015;170(1):110–117.
  • Kayal S, Sengar M, Jain H, et al. Induction related mortality in acute myeloid leukemia: multivariate model of predictive score from the Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC). Blood. 2019;134(Supplement_1):2615–2615.
  • Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
  • Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis. 2020;71(6):1367–1376.
  • Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019;33(12):2795–2804.
  • Winters AC, Gutman JA, Purev E, et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 2019;3(20):2911–2919.
  • Wu X, Zhang J, Chen Q, et al. Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia. Br J Haematol. 2020;189(5):e200–e204.
  • Karol SE, Alexander TB, Budhraja A, et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncol. 2020;21(4):551–560.
  • Gardin C, Dombret H. Hypomethylating agents as a therapy for AML. Curr Hematol Malig Rep. 2017;12(1):1–10.
  • Pollyea DA, Amaya M, Strati P, et al. Venetoclax for AML: changing the treatment paradigm. Blood Adv. 2019;3(24):4326–4335.
  • Tandon S. Acute leukemia treatment in low- and middle-income countries: is it time for tailored therapy? Cancer Res Stat Treat. 2020;3:642.
  • Ferrara F, Zappasodi P, Roncoroni E, et al. Impact of Covid-19 on the treatment of acute myeloid leukemia. Leukemia. 2020;34(8):2254–2256.
  • Ganzel C, Ram R, Gural A, et al. Venetoclax is safe and efficacious in relapsed/refractory AML. Leuk Lymphoma. 2020;61(9):2221–2225.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.